AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 ...

AbbVie hiked its full-year outlook on the back of better-than-expected earnings early Thursday, sending shares of the ...

AbbVie Inc. is in talks to acquire next-generation psychedelics developer Gilgamesh Pharmaceuticals, according to people ...

AbbVie raised its 2025 earnings forecast after a strong Q2, despite $3 billion in deal costs tied to acquisitions of Capstan ...

AbbVie (ABBV) came out with quarterly earnings of $2.97 per share, beating the Zacks Consensus Estimate of $2.89 per share. This compares to earnings of $2.65 per share a year ago. These figures are ...

AbbVie's beat Wall Street's estimates for its top- and bottom-lines in its latest quarter, boosted by sales of Skyrizi and Rinvoq. The North Chicago, Ill., drugmaker said it logged earnings of $938 ...

AbbVie (ABBV) stock gains as the company raises outlook and reports better than expected Q2 2025 results, driven by its ...

AbbVie raised its 2025 profit forecast on Thursday, after beating Wall Street estimates for second-quarter results on strong ...

AbbVie’s beat Wall Street’s estimates for its top- and bottom-lines in the second quarter, boosted by sales of Skyrizi and ...

AbbVie Inc. (ABBV) on Thursday reported second-quarter earnings of $938 million. The North Chicago, Illinois-based company said it had net ...

AbbVie has reportedly added Gilgamesh Pharmaceuticals to its shopping list. | AbbVie has reportedly added Gilgamesh ...

AbbVie has reported topline outcomes from the first of two trials of the Phase III UP-AA programme, assessing Rinvoq (upadacitinib).